Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 121Recruiting 37Terminated 31Unknown 15Active not recruiting 15Withdrawn 9Not yet recruiting 3Suspended 2Enrolling by invitation 2Available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 73Gastrointestinal 8Genitourinary 7Thoracic 5Gynecologic 4Dermatologic 3Sarcoma 2NET 2Lymphoid 2Endocrine 2Other solid neoplasm 1Other hematologic neoplasm 1Other 1Head & Neck 1CNS 1

Conditions

Sarcoma 9Bone Neoplasms 3Neoplasms 2Breast Neoplasms 2Venous Thromboembolism 1Risk Reduction Behavior 1Rhabdomyosarcoma 1Prosthesis-Related Infections 1Osteosarcoma 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Lymphoma 1Hematoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × Breast Neoplasms × Sarcoma × Clear all
NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Stella Pharma Corporation

Phase 1/2 Enrolling by invitation
30 enrolled
BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Enrolling by invitation
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡